The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.

Vaccine
Anthony H-C ChoiR L Ward

Abstract

Intranasal (i.n.) immunization of BALB/c mice with chimeric murine rotavirus EDIM (epizootic diarrhea of infant mice) VP6 and attenuated E. coli heat-labile toxin (LT), LT(R192G), stimulated >99% protection against rotavirus shedding after EDIM challenge. Here, we evaluated other potential adjuvants with chimeric VP6 administered by two mucosal routes: i.n. and oral. Besides LT(R192G), the adjuvants examined included Adjumer, CpG oligodeoxynucleotides (CpG ODN), chimeric A1 subunit of cholera toxin (CTA1)-DD, and QS-21. All except QS-21 significantly (P<0.05) increased VP6-specific serum IgG responses after i.n. immunization, but none significantly increased these responses when administered orally. The i.n. delivery of chimeric VP6 alone induced both rotavirus IgG1 and IgG2a whose relative titers suggested a skewed Th2-like response. Inclusion of Adjumer greatly increased Th2-like responses, while CpG ODN shifted the response to a less Th2-like response. The adjuvants CTA1-DD, LT(R192G), QS-21 had no significant effect on ratios of IgG1/IgG2a titers. Following EDIM challenge of mice immunized i.n. with chimeric VP6 and either LT(R192G), CTA1-DD, Adjumer or CpG ODN, shedding was reduced >99, 95, 80, 74, respectively, relative t...Continue Reading

References

Oct 1, 1990·Journal of Virology·R L WardJ F Sheridan
Oct 3, 1999·Vaccine·M J McCluskie, H L Davis
Dec 15, 2000·Vaccine·M J McCluskieH L Davis
Feb 24, 2001·The New England Journal of Medicine·T V MurphyUNKNOWN Rotavirus Intussusception Investigation Team
May 18, 2001·The New England Journal of Medicine

❮ Previous
Next ❯

Citations

Jun 21, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Andrea S LaimbacherCornel Fraefel
Mar 4, 2014·Microbial Pathogenesis·Sayed-Mahdi MarashiZabihollah Shoja
Mar 7, 2007·Vaccine·Maureen DennehyAnna-Lise Williamson
Nov 3, 2011·Expert Review of Vaccines·Luigi BuonaguroFranco M Buonaguro
Feb 1, 2005·Annals of the New York Academy of Sciences·Nils Lycke
Apr 8, 2015·Vaccine·O Badillo-GodinezF Esquivel-Guadarrama
May 30, 2015·Vaccine·Somayeh JalilvandZabihollah Shoja
Jul 29, 2009·Journal of Pediatric Surgery·Alexander J BondocGreg M Tiao
Jan 8, 2019·Reviews in Medical Virology·Atefeh AfchangiZabihollah Shoja
Feb 10, 2006·Pediatric Annals·David I Bernstein, Richard L Ward
Nov 19, 2003·Scandinavian Journal of Infectious Diseases·Arthur M Krieg
Dec 8, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Alexander K Andrianov, Robert Langer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.